
AI Drug Discovery Pioneer InSilico Medicine Launches Hong Kong IPO, With Backing From Lilly, Tencent
AI biotech firm InSilico Medicine is launching a major Hong Kong IPO, backed by cornerstone investments from Eli Lilly and Tencent, among others.
Showing 12 of 13450 posts

AI biotech firm InSilico Medicine is launching a major Hong Kong IPO, backed by cornerstone investments from Eli Lilly and Tencent, among others.

In today's seemingly solidified landscape of shooter games, a title named Delta Force is breaking the silence with a formidable presence. It marks not only the ...

CATL has launched the world's first production line using embodied AI humanoid robots, achieving over 99% success in a critical battery testing process.

Muxi, a Chinese high-performance GPU maker, lists on STAR Market with shares surging over 500% to a valuation exceeding 270 billion RMB (≈$37 billion USD), despite a 9-month loss of 350 million RMB (≈$48 million USD).

XPeng’s second-gen VLA with L4 capabilities is expected to fully deploy in vehicles by Q1 2026, following Guangzhou L3 testing and China’s first L3 commercialization pilots.

Huawei announces the WATCH 10th Anniversary Edition smartwatch, set for reveal on December 22 alongside the nova 15 series, featuring a commemorative design similar to the WATCH 5.

ByteDance releases Seedance 1.5 Pro, a multimodal model for joint audio-video generation from text or images, now live on Jimeng AI and Doubao.
OneRobotics passes HKEX hearing and is set to become the “first AI embodied home robot stock,” with strong products like Acemate and Kata Friends driving global growth.
Shanghai AI Lab open-sources MemVerse, a bionic multimodal memory framework that equips AI agents with hippocampus-like lifelong memory, slashing response times and boosting cross-modal performance.

Biren Technology has received regulatory approval for a Hong Kong IPO, marking a major milestone for one of China’s leading homegrown GPU developers in its bid to become the country’s first listed pure-play GPU company.

RoboParty has raised back-to-back Seed and Seed+ rounds within a month to scale its fully open-source humanoid robotics platform and developer ecosystem.

Phil Rivers Tech has raised an eight-figure Series A1 round to accelerate AI4S-powered drug discovery and push multiple innovative therapies into clinical development.